![New robot comes to cardiac intensive care unit](https://blogger.googleusercontent.com/img/proxy/AVvXsEjTA8iarT2sCEdRwZjE6BmvfLUN3lopA2HFM8srVvU8Bfi_iZgQCQDjpdgKh8kJlJUooc7XGGf643xd5tOsCjT4eDu9Sv23nC79axBLtO99CHlfW_UVnEbGzON6YWbUWzErL8AaslgoZG65EDXLZouw7K_kcSrpMFYfgZs9CMNkBxrCW6dqcXB9oe2w-paj3WbCgeOkLY9pXBJlYJ9DNIq09moQ3vWPAuB2EE-pVQ=s0-d-e1-ft) |
The telemedicine robot at Children’s National arrived in late August and completed a successful test run in the cardiac intensive care unit. Named Dr. Bear Bot by patients, the robot works as a virtual liaison traveling between rooms to connect patients and attending care teams to critical cardiac care specialists located in a virtual command center. The technology allows doctors to monitor patient vitals and progress remotely, enhancing their ability to diagnose, care for and intervene during critical events. Over time, the medical will analyze factors including short- and long-term health outcomes, mortality rates, care coordination and patient flow, and serve as a model for future command centers offering critical care. |
|
![Experimental drug shows promise for slowing cardiac disease and inflammation](https://blogger.googleusercontent.com/img/proxy/AVvXsEiuN1JFt0e7LcXiRHHbbQ_hslXX_WGUiL1UDAklJv7hAYbYAXj4SzlZr9xDPj-fwJumEom4nOsoON-FPEmsMR1bM4lat4beva-nX3U4-qAyTFaYBn2AaiiiLEbZU1V7p9wiw-ttgEiJk6LQzQlDq6keB1g0WgiJU8j_CfRa2t19vqgXyE7gRpBEKS5up4USx1A_hWiE6A=s0-d-e1-ft) |
Vamorolone, an experimental medicine under development, appears to combine the beneficial effects of prednisone and eplerenone – standard treatments for Duchenne muscular dystrophy (DMD) – in the heart and muscles, while also showing improved safety in experimental models. The drug does so by simultaneously targeting two nuclear receptors important in regulating inflammation and cardiomyopathy. |
|
![Cortical dysmaturation in congenital heart disease](https://blogger.googleusercontent.com/img/proxy/AVvXsEgGbMXJJDPEPh3ynASYH2AWSdlIMVkC5DKvJB4RTLIdwdhTNfo-VnaHav2fikoPTMOC9lMrdmCf3hJD2aRPzyRT2BFelPnTMKf1ANY6dR6r7fNfLo8j66MQL_r9lkmpBxDUpnY3ES92GU6PTbGOXQteg6vFplWJRCY2iTcafxUP4pwnrrBUcFsjPAkHp45WDmOHZRKeXB30gRKe=s0-d-e1-ft) |
Recently, Nobuyuki Ishibashi, M.D., published a review in Trends in Neurosciences about the mechanisms of cortical dysmaturation that can occur in children born with congenital heart disease. By understanding the early-life impact and relationship between cardiac abnormalities and cortical neuronal development, Dr. Ishibashi and the study authors hope to influence strategies for neonatal neuroprotection. |
|
![Breakthrough device objectively measures pain type, intensity and drug effects](https://blogger.googleusercontent.com/img/proxy/AVvXsEgJw2fOaJzsg181q9g9fD7GGRMuB-3jLz71xKbxZJ8sCHHg4B5vQELO6-x3EoC6cpRZTb60zIcU-1CQriGKqy_raf_h5WQ01U87a6YN1maEhAkIlx2NBF2Zr8mwWEh2eO7ZQqxnwuVhDLvDDT_OZenS_Xf_wQDGqFHaEWl26CdpLBL41vR_HIg0CoNXSw=s0-d-e1-ft) |
Pediatric anesthesiologist Julia C. Finkel, M.D., has developed AlgometRx, a first-of-its-kind handheld device that measures a patient’s pupillary response and, using proprietary algorithms, provides a diagnostic measurement of pain intensity, and type. (AP Photo/Manuel Balce Ceneta.) |
|
![The Leapfrog Group names Children’s National Health System a 2018 “Top Children’s Hospital”](https://blogger.googleusercontent.com/img/proxy/AVvXsEgyc8OXC3JyWD30aFry4rUvzM839lxul5NgyxNrHgdhEW9KEJ3A9Mv44hWiUtJRgYlCXV1sML_uukYt0Hkp7EA_IsChehG1wg5-6H1vhIUlXu14c5OkagXbEajAYbdGOUPBU1M0HvQ295PvBOulrOC6gikP3AeTa5Uwts8G7801Lcjog62aILeiL0IV=s0-d-e1-ft) |
Children’s National was named a 2018 “Top Children’s Hospital” by The Leapfrog Group, an independent watchdog organization. The highest performing hospitals on the Leapfrog Hospital Survey are recognized annually for this prestigious award. |
|
|
No hay comentarios:
Publicar un comentario